Ozturk et al also described a case of a 32-year-old male patient with MS who had been on IFN-β-1a therapy for 6 years, who had proteinuria (3 + protein) on urine dipstick test and quantitative proteinuria of 1671 mg/day, which subsequently worsened to 3 g/day a month later.[12] This necessitated the cessation of IFN therapy, as no other risk factors were identified. This evidence concerns the gene IFNA1 and myeloid sarcoma.